110 related articles for article (PubMed ID: 11853121)
61. Evidence against cannabinoid receptor involvement in intraocular pressure effects of cannabinoids in rabbits.
Hodges LC; Reggio PH; Green K
Ophthalmic Res; 1997; 29(1):1-5. PubMed ID: 9112260
[TBL] [Abstract][Full Text] [Related]
62. Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats.
Cheer JF; Wassum KM; Heien ML; Phillips PE; Wightman RM
J Neurosci; 2004 May; 24(18):4393-400. PubMed ID: 15128853
[TBL] [Abstract][Full Text] [Related]
63. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus.
Hájos N; Ledent C; Freund TF
Neuroscience; 2001; 106(1):1-4. PubMed ID: 11564411
[TBL] [Abstract][Full Text] [Related]
64. R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor.
Sánchez AJ; González-Pérez P; Galve-Roperh I; García-Merino A
Biochem Pharmacol; 2006 Dec; 72(12):1697-706. PubMed ID: 17007821
[TBL] [Abstract][Full Text] [Related]
65. Agmatine and a cannabinoid agonist, WIN 55212-2, interact to produce a hypothermic synergy.
Rawls SM; Tallarida RJ; Zisk J
Eur J Pharmacol; 2006 Dec; 553(1-3):89-98. PubMed ID: 17109846
[TBL] [Abstract][Full Text] [Related]
66. N-methyl-D-aspartate antagonists and WIN 55212-2 [4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1-i,j]quinolin-6-one], a cannabinoid agonist, interact to produce synergistic hypothermia.
Rawls SM; Cowan A; Tallarida RJ; Geller EB; Adler MW
J Pharmacol Exp Ther; 2002 Oct; 303(1):395-402. PubMed ID: 12235276
[TBL] [Abstract][Full Text] [Related]
67. Direct actions of cannabinoids on synaptic transmission in the nucleus accumbens: a comparison with opioids.
Hoffman AF; Lupica CR
J Neurophysiol; 2001 Jan; 85(1):72-83. PubMed ID: 11152707
[TBL] [Abstract][Full Text] [Related]
68. Autoradiographic analysis of cannabinoid receptor binding and cannabinoid agonist-stimulated [35S]GTP gamma S binding in morphine-dependent mice.
Romero J; Fernández-Ruiz JJ; Vela G; Ruiz-Gayo M; Fuentes JA; Ramos JA
Drug Alcohol Depend; 1998 May; 50(3):241-9. PubMed ID: 9649978
[TBL] [Abstract][Full Text] [Related]
69. Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats.
Solinas M; Panlilio LV; Tanda G; Makriyannis A; Matthews SA; Goldberg SR
Neuropsychopharmacology; 2005 Nov; 30(11):2046-57. PubMed ID: 15870833
[TBL] [Abstract][Full Text] [Related]
70. Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia.
Gomes FV; Guimarães FS; Grace AA
Int J Neuropsychopharmacol; 2014 Dec; 18(2):. PubMed ID: 25522381
[TBL] [Abstract][Full Text] [Related]
71. Behavioral effects in adult rats of chronic prepubertal treatment with the cannabinoid receptor agonist WIN 55,212-2.
Schneider M; Drews E; Koch M
Behav Pharmacol; 2005 Sep; 16(5-6):447-54. PubMed ID: 16148450
[TBL] [Abstract][Full Text] [Related]
72. Effects of cannabinoids on non-adrenergic non-cholinergic-mediated relaxation in guinea-pig trachea.
Nieri P; Martinotti E; Testai L; Martinelli C; Breschi MC
Eur J Pharmacol; 2003 Aug; 475(1-3):115-8. PubMed ID: 12954367
[TBL] [Abstract][Full Text] [Related]
73. Role of intra-accumbal cannabinoid CB1 receptors in the potentiation, acquisition and expression of morphine-induced conditioned place preference.
Karimi S; Azizi P; Shamsizadeh A; Haghparast A
Behav Brain Res; 2013 Jun; 247():125-31. PubMed ID: 23523958
[TBL] [Abstract][Full Text] [Related]
74. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.
Tanda G; Pontieri FE; Di Chiara G
Science; 1997 Jun; 276(5321):2048-50. PubMed ID: 9197269
[TBL] [Abstract][Full Text] [Related]
75. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats.
Chaperon F; Soubrié P; Puech AJ; Thiébot MH
Psychopharmacology (Berl); 1998 Feb; 135(4):324-32. PubMed ID: 9539255
[TBL] [Abstract][Full Text] [Related]
76. Inhibition of interleukin-1β-induced endothelial tissue factor expression by the synthetic cannabinoid WIN 55,212-2.
Scholl A; Ivanov I; Hinz B
Oncotarget; 2016 Sep; 7(38):61438-61457. PubMed ID: 27556861
[TBL] [Abstract][Full Text] [Related]
77. Dysregulation of the endogenous cannabinoid system in adult rats prenatally treated with the cannabinoid agonist WIN 55,212-2.
Castelli MP; Paola Piras A; D'Agostino A; Pibiri F; Perra S; Gessa GL; Maccarrone M; Pistis M
Eur J Pharmacol; 2007 Nov; 573(1-3):11-9. PubMed ID: 17644084
[TBL] [Abstract][Full Text] [Related]
78. Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic neurons.
Muntoni AL; Pillolla G; Melis M; Perra S; Gessa GL; Pistis M
Eur J Neurosci; 2006 May; 23(9):2385-94. PubMed ID: 16706846
[TBL] [Abstract][Full Text] [Related]
79. Cannabinoid-induced changes in respiration of brain mitochondria.
Fišar Z; Singh N; Hroudová J
Toxicol Lett; 2014 Nov; 231(1):62-71. PubMed ID: 25195527
[TBL] [Abstract][Full Text] [Related]
80. WIN-55,212-2 and SR-141716A alter nicotine-induced changes in locomotor activity, but do not alter nicotine-evoked [3H]dopamine release.
Rodvelt KR; Bumgarner DM; Putnam WC; Miller DK
Life Sci; 2007 Jan; 80(4):337-44. PubMed ID: 17067637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
